aqing
2023-08-21
yes！
Moderna: Buy Before The Fall Covid-19 Wave
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":211297982779480,"tweetId":"211297982779480","gmtCreate":1692611493066,"gmtModify":1692611494352,"author":{"id":3439807817472944,"idStr":"3439807817472944","authorId":3439807817472944,"authorIdStr":"3439807817472944","name":"aqing","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":6,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>yes！</p></body></html>","htmlText":"<html><head></head><body><p>yes！</p></body></html>","text":"yes！","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/211297982779480","repostId":2361525843,"repostType":2,"repost":{"id":"2361525843","pubTimestamp":1692606128,"share":"https://www.laohu8.com/m/news/2361525843?lang=&edition=full","pubTime":"2023-08-21 16:22","market":"us","language":"en","title":"Moderna: Buy Before The Fall Covid-19 Wave","url":"https://stock-news.laohu8.com/highlight/detail?id=2361525843","media":"seekingalpha","summary":"Finance reports profit margins at around 11%. Moderna also bought back $600 million worth of MRNA stock during Q2 2023. Companies routinely perform stock buybacks when management believes shares are undervalued. The company held $14 billion in cash on its balance sheet at the end of Q2 2023 with $1.7 billion in long term debt. I expect net profit margins to improve drastically heading into the end of Q3 2023 once the fall COVID-19 wave arrives. Have Moderna Shares Bottomed Due to a Projected COVID-19 Fall Wave?Health experts are predicting a massive spike in COVID-19 cases starting around September 1st as the weather changes and everyone heads back to school and the workplace. The newest COVID-19 variant, Eris, has caused a spike in COVID-19 cases worldwide with countries such as the United States, Canada, United Kingdom, and many others reporting spikes in cases and hospitalizations. Moderna made a swift move by working on its most recent vaccine to fight Eris and early","content":"<html><body><ul><li>Moderna's COVID-19 vaccine was found to be over 95% effective at preventing illness, hospitalizations, and deaths.</li><li>Experts predict another COVID-19 wave starting in September 2023, leading to increased revenue for Moderna.</li><li>MRNA upgraded its sales guidance for the second half of 2023 to $6-8 billion, anticipating a spike in COVID-19 cases.</li></ul><p><figure><picture><img height=\"2274px\" loading=\"lazy\" sizes=\"(max-width: 768px) calc(100vw - 36px), (max-width: 1024px) calc(100vw - 132px), (max-width: 1200px) calc(66.6vw - 72px), 600px\" src=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1223699960/image_1223699960.jpg?io=getty-c-w750\" srcset=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1223699960/image_1223699960.jpg?io=getty-c-w1536 1536w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1223699960/image_1223699960.jpg?io=getty-c-w1280 1280w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1223699960/image_1223699960.jpg?io=getty-c-w1080 1080w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1223699960/image_1223699960.jpg?io=getty-c-w750 750w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1223699960/image_1223699960.jpg?io=getty-c-w640 640w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1223699960/image_1223699960.jpg?io=getty-c-w480 480w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1223699960/image_1223699960.jpg?io=getty-c-w320 320w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1223699960/image_1223699960.jpg?io=getty-c-w240 240w\" width=\"3411px\"/></picture><figcaption><p>Maddie Meyer</p></figcaption></figure></p> <p>Moderna (<span>NASDAQ:MRNA</span>) was one of the top performing biotech stocks during the 2020 COVID-19 wave that sent many soaring to the moon. The company produces vaccines that prevent COVID-19 symptoms by releasing mRNA into the human body to<span> create a spike protein for optimal immune response.</span></p> <p>According to Healthline, researchers found that the Moderna vaccine was over 95% effective at preventing illness, hospitalizations, and COVID-19 related deaths.</p> <p>Unfortunately, experts predict another massive COVID-19 wave starting in September 2023 when schools reopen, and employees return to the workplace.</p> <p>That means companies like Moderna will likely experience a sharp boost in revenue due to people rushing to get mRNA vaccines in an attempt to beat the upcoming COVID-19 wave.</p> <p>While many stocks got crushed during the 2020 COVID-19 pandemic, Moderna experienced a massive increase in share price from $20 to over $450 at<span> its peak.</span></p> <p><figure><img height=\"366\" loading=\"lazy\" src=\"https://static.seekingalpha.com/uploads/2023/8/20/saupload_4e6d89d7d9ffb8b1b5a6e62e7f99ce60.png\" width=\"635\"/><figcaption>Data by YCharts</figcaption></figure></p> <p>To make things clear, I'm neither for nor against getting vaccinated as a way to prevent the COVID-19 virus. This article is meant for equity analysis only and I'm not taking a political or humanitarian stance on the jab.</p> <h2>Moderna Upgraded Its Guidance for Q3 & Q4 2023</h2> <p>Seasonality has a major effect on Moderna's revenue and net income due to spikes and dips into COVID-19 vaccination needs. The company posted Q2 2023 revenue of $344 million with a net loss of $1.38 billion.</p> <p>In the latest Q2 2023 earnings call, Moderna CEO Stephen Hoge increased sales guidance to around $6-$8 billion in the 2nd half of 2023 in anticipation of a spike in COVID-19 cases. Gross margins are projected to be around 60 to 65% while Yahoo! Finance reports profit margins at around 11%.</p> <p>Moderna also bought back $600 million worth of MRNA stock during Q2 2023. Companies routinely perform stock buybacks when management believes shares are undervalued.</p> <p>The company held $14 billion in cash on its balance sheet at the end of Q2 2023 with $1.7 billion in long term debt.</p> <p>I expect net profit margins to improve drastically heading into the end of Q3 2023 once the fall COVID-19 wave arrives.</p> <h2>Have Moderna Shares Bottomed Due to a Projected COVID-19 Fall Wave?</h2> <p>Health experts are predicting a massive spike in COVID-19 cases starting around September 1st as the weather changes and everyone heads back to school and the workplace.</p> <p>The newest COVID-19 variant, <em>Eris</em>, has caused a spike in COVID-19 cases worldwide with countries such as the United States, Canada, United Kingdom, and many others reporting spikes in cases and hospitalizations.</p> <p>Moderna made a swift move by working on its most recent vaccine to fight Eris and early clinic trials reported high success rates in response to the newest virus strain.</p> <p>MRNA shares crashed to a 52-week low of $95 until the news broke and sent shares just above $100 currently. Moderna shares look attractive at an RSI of 31 on the MRNA weekly chat.</p> <p><figure contenteditable=\"false\"><picture><span><img contenteditable=\"false\" height=\"308\" loading=\"lazy\" src=\"https://static.seekingalpha.com/uploads/2023/8/20/45278896-16925059235144863.png\" width=\"640\"/></span></picture><figcaption><p>Moderna Weekly Chart (tradingview.com)</p></figcaption></figure></p> <p>I'm predicting an inverse effect where MRNA shares will trade higher as we head into Q4 while most big tech stocks such as Tesla (TSLA) and Apple (AAPL) continue selling off on the worrisome news.</p> <p>MRNA was one of the few stocks that didn't experience the March 2023 COVID-19 crunch but rather increased revenue to $20 billion and $18 billion, respectively, during 2021 and 2022.</p> <h2>Risk Factors</h2> <p>Moderna is arguably the best pure COVID-19 stock to own in my opinion but there are several risk factors that investors should play take note of:</p> <ul> <li> <strong>Insider Selling</strong>: Moderna President Stephen Hoge sold 15,000 MRNA on August 17th at the price of $100. Insider selling is a bearish signal, but the good news is he still owns 1.5 million MRNA shares. If insiders continue selling, then perhaps MRNA shares could crash below $100 until they find a bottom.</li> <li> <strong>NASDAQ Panic Selloff</strong>: Hedge fund manager Michael Burry opened a massive put position on the QQQ and SPY in late August signaling his bearish market sentiment. While Moderna isn't a part of the QQQ, I think most investors are turning bearish on stocks in general.</li> <li> <strong>Falling COVID-19 Cases</strong>: COVID-19 cases are up nearly 100% in August 2023 versus July 2023, but we aren't sure what will happen moving forward. If COVID-19 cases don't increase, then the demand for Moderna vaccines will remain lower than projected.</li> <li> <strong>Failure to Receive FDA approval for Eris Vaccine:</strong> Early trials show for the Eris vaccine turned out positive, but Moderna must wait for FDA approval. If Moderna's vaccine gets rejected, then the company cannot fulfill its raised guidance projections.</li> <li> <strong>Attractive Bond and Money Market Yields</strong>: Wall Street Journal reported that Americans moved $36 billion into money market funds in August to take advantage of 4%+ yields with very low risk.</li> </ul> <h2>My Gameplan for MRNA Stock</h2> <p>All signs point to a massive increase in MRNA's stock price if the fall COVID-19 wave predictions come true. I'm holding several MRNA call options at various strike prices of around $105 to $107 over the next few weeks.</p> <p>I'm also taking a look at some longer-term options around the $200 strike price expiring in January 2024 and April 2024.</p> <p>If Moderna's vaccine gets approved in early September, then Q3 and Q4 2023 earnings reports should easily beat Wall Street analysts' estimates.</p> <p>MRNA trades at a forward P/E ratio of 8 and I think Moderna is one of the best value stocks on the market right now.</p> <p><figure><img height=\"366\" loading=\"lazy\" src=\"https://static.seekingalpha.com/uploads/2023/8/20/saupload_0714fef94eacec9edb9c01f5e8712558.png\" width=\"635\"/><figcaption>Data by YCharts</figcaption></figure></p> <div></div> <p>Moderna is a cash cow company that raked in $12.2 billion in profits for 2021 and $8.3 billion in profits for 2022. Another COVID-19 outbreak would provide substantial upside in my opinion considering how the market reacted to COVID-19 at the beginning of 2020.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna: Buy Before The Fall Covid-19 Wave</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna: Buy Before The Fall Covid-19 Wave\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-08-21 16:22 GMT+8 <a href=https://seekingalpha.com/article/4629928-moderna-stock-buy-before-fall-covid-19-wave><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna's COVID-19 vaccine was found to be over 95% effective at preventing illness, hospitalizations, and deaths.Experts predict another COVID-19 wave starting in September 2023, leading to increased...</p>\n\n<a href=\"https://seekingalpha.com/article/4629928-moderna-stock-buy-before-fall-covid-19-wave\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1223699960/image_1223699960.jpg","relate_stocks":{"LU0127658192.USD":"EASTSPRING INVESTMENTS GLOBAL TECHNOLOGY \"A\" (USD) ACC","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","IE00BJTD4N35.SGD":"Neuberger Berman US Long Short Equity A1 Acc SGD-H","BK4512":"苹果概念","TSLA":"特斯拉","BK4511":"特斯拉概念","IE00B775SV38.USD":"NEUBERGER BERMAN US MULTICAP OPPORTUNITIES \"A\" (USD) ACC","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","IE00B3S45H60.SGD":"Neuberger Berman US Multicap Opportunities A Acc SGD-H","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","BK4548":"巴美列捷福持仓","LU0109391861.USD":"富兰克林美国机遇基金A Acc","LU1429558221.USD":"Natixis Loomis Sayles US Growth Equity RA USD","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","IE00B19Z9505.USD":"美盛-美国大盘成长股A Acc","LU0353189680.USD":"富国美国全盘成长基金Cl A Acc","IE00BJJMRX11.SGD":"Janus Henderson Balanced A Acc SGD","BNTX":"BioNTech SE","LU1435385759.SGD":"Natixis Loomis Sayles US Growth Equity RA SGD-H","LU0082616367.USD":"摩根大通美国科技A（dist）","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","BK4532":"文艺复兴科技持仓","BK4554":"元宇宙及AR概念","IE00B1XK9C88.USD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A\" (USD) ACC","BK4553":"喜马拉雅资本持仓","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU2249611893.SGD":"BNP PARIBAS ENERGY TRANSITION \"CRH\" (SGD) ACC","BK4534":"瑞士信贷持仓","LU0823411888.USD":"法巴消费创新基金 Cap","MRNA":"Moderna, Inc.","BK4555":"新能源车","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0353189763.USD":"ALLSPRING US ALL CAP GROWTH FUND \"I\" (USD) ACC","AAPL":"苹果","IE0004445015.USD":"JANUS HENDERSON BALANCED \"A2\" (USD) ACC","LU0011850046.USD":"贝莱德全球长线股票 A2 USD","BK4535":"淡马锡持仓","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU0823414478.USD":"法巴经典能源转换基金","IE00BJTD4V19.USD":"NEUBERGER BERMAN US LONG SHORT EQUITY \"A1\" (USD) ACC","LU0097036916.USD":"贝莱德美国增长A2 USD","LU0511384066.AUD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (AUDHDG) ACC","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU1861558580.USD":"日兴方舟颠覆性创新基金B","IE0009356076.USD":"JANUS HENDERSON GLOBAL TECHNOLOGY AND INNOVATION \"A2\" (USD) ACC","LU0149725797.USD":"汇丰美国股市经济规模基金"},"source_url":"https://seekingalpha.com/article/4629928-moderna-stock-buy-before-fall-covid-19-wave","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2361525843","content_text":"Moderna's COVID-19 vaccine was found to be over 95% effective at preventing illness, hospitalizations, and deaths.Experts predict another COVID-19 wave starting in September 2023, leading to increased revenue for Moderna.MRNA upgraded its sales guidance for the second half of 2023 to $6-8 billion, anticipating a spike in COVID-19 cases.Maddie Meyer Moderna (NASDAQ:MRNA) was one of the top performing biotech stocks during the 2020 COVID-19 wave that sent many soaring to the moon. The company produces vaccines that prevent COVID-19 symptoms by releasing mRNA into the human body to create a spike protein for optimal immune response. According to Healthline, researchers found that the Moderna vaccine was over 95% effective at preventing illness, hospitalizations, and COVID-19 related deaths. Unfortunately, experts predict another massive COVID-19 wave starting in September 2023 when schools reopen, and employees return to the workplace. That means companies like Moderna will likely experience a sharp boost in revenue due to people rushing to get mRNA vaccines in an attempt to beat the upcoming COVID-19 wave. While many stocks got crushed during the 2020 COVID-19 pandemic, Moderna experienced a massive increase in share price from $20 to over $450 at its peak. Data by YCharts To make things clear, I'm neither for nor against getting vaccinated as a way to prevent the COVID-19 virus. This article is meant for equity analysis only and I'm not taking a political or humanitarian stance on the jab. Moderna Upgraded Its Guidance for Q3 & Q4 2023 Seasonality has a major effect on Moderna's revenue and net income due to spikes and dips into COVID-19 vaccination needs. The company posted Q2 2023 revenue of $344 million with a net loss of $1.38 billion. In the latest Q2 2023 earnings call, Moderna CEO Stephen Hoge increased sales guidance to around $6-$8 billion in the 2nd half of 2023 in anticipation of a spike in COVID-19 cases. Gross margins are projected to be around 60 to 65% while Yahoo! Finance reports profit margins at around 11%. Moderna also bought back $600 million worth of MRNA stock during Q2 2023. Companies routinely perform stock buybacks when management believes shares are undervalued. The company held $14 billion in cash on its balance sheet at the end of Q2 2023 with $1.7 billion in long term debt. I expect net profit margins to improve drastically heading into the end of Q3 2023 once the fall COVID-19 wave arrives. Have Moderna Shares Bottomed Due to a Projected COVID-19 Fall Wave? Health experts are predicting a massive spike in COVID-19 cases starting around September 1st as the weather changes and everyone heads back to school and the workplace. The newest COVID-19 variant, Eris, has caused a spike in COVID-19 cases worldwide with countries such as the United States, Canada, United Kingdom, and many others reporting spikes in cases and hospitalizations. Moderna made a swift move by working on its most recent vaccine to fight Eris and early clinic trials reported high success rates in response to the newest virus strain. MRNA shares crashed to a 52-week low of $95 until the news broke and sent shares just above $100 currently. Moderna shares look attractive at an RSI of 31 on the MRNA weekly chat. Moderna Weekly Chart (tradingview.com) I'm predicting an inverse effect where MRNA shares will trade higher as we head into Q4 while most big tech stocks such as Tesla (TSLA) and Apple (AAPL) continue selling off on the worrisome news. MRNA was one of the few stocks that didn't experience the March 2023 COVID-19 crunch but rather increased revenue to $20 billion and $18 billion, respectively, during 2021 and 2022. Risk Factors Moderna is arguably the best pure COVID-19 stock to own in my opinion but there are several risk factors that investors should play take note of: Insider Selling: Moderna President Stephen Hoge sold 15,000 MRNA on August 17th at the price of $100. Insider selling is a bearish signal, but the good news is he still owns 1.5 million MRNA shares. If insiders continue selling, then perhaps MRNA shares could crash below $100 until they find a bottom. NASDAQ Panic Selloff: Hedge fund manager Michael Burry opened a massive put position on the QQQ and SPY in late August signaling his bearish market sentiment. While Moderna isn't a part of the QQQ, I think most investors are turning bearish on stocks in general. Falling COVID-19 Cases: COVID-19 cases are up nearly 100% in August 2023 versus July 2023, but we aren't sure what will happen moving forward. If COVID-19 cases don't increase, then the demand for Moderna vaccines will remain lower than projected. Failure to Receive FDA approval for Eris Vaccine: Early trials show for the Eris vaccine turned out positive, but Moderna must wait for FDA approval. If Moderna's vaccine gets rejected, then the company cannot fulfill its raised guidance projections. Attractive Bond and Money Market Yields: Wall Street Journal reported that Americans moved $36 billion into money market funds in August to take advantage of 4%+ yields with very low risk. My Gameplan for MRNA Stock All signs point to a massive increase in MRNA's stock price if the fall COVID-19 wave predictions come true. I'm holding several MRNA call options at various strike prices of around $105 to $107 over the next few weeks. I'm also taking a look at some longer-term options around the $200 strike price expiring in January 2024 and April 2024. If Moderna's vaccine gets approved in early September, then Q3 and Q4 2023 earnings reports should easily beat Wall Street analysts' estimates. MRNA trades at a forward P/E ratio of 8 and I think Moderna is one of the best value stocks on the market right now. Data by YCharts Moderna is a cash cow company that raked in $12.2 billion in profits for 2021 and $8.3 billion in profits for 2022. Another COVID-19 outbreak would provide substantial upside in my opinion considering how the market reacted to COVID-19 at the beginning of 2020.","news_type":1},"isVote":1,"tweetType":1,"viewCount":397,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/211297982779480"}
精彩评论